Who are Tyroserleutide for injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Victoza (liraglutide), liraglutide monotherapy, Liraglutide injection, Lixisenatide (AVE0010), semaglutide combined with metformin, Liraglutide + Exercise training.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tyroserleutide-for-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Tyroserleutide for injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tyroserleutide for injection (Tyroserleutide for injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GLP-1 receptor agonist. Area: Diabetes.

phase 3 GLP-1 receptor agonist GLP-1R Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Tyroserleutide for injection (Tyroserleutide for injection) — Shenzhen Kangzhe Pharmaceutical Co., Ltd.. Tyroserleutide for injection is a recombinant human proinsulin-derived peptide that mimics the action of incretin hormones to enhance glucose-dependent insulin secretion.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tyroserleutide for injection TARGET	Tyroserleutide for injection	Shenzhen Kangzhe Pharmaceutical Co., Ltd.	phase 3	GLP-1 receptor agonist	GLP-1R
Victoza (liraglutide)	Victoza (liraglutide)	Zealand University Hospital	marketed	GLP-1 receptor agonist	GLP-1R
liraglutide monotherapy	liraglutide monotherapy	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	marketed	GLP-1 receptor agonist	GLP-1R
Liraglutide injection	Liraglutide injection	Unidad de Cirugia Bariatrica Hospital Civil Dr. Juan I. Menchaca	marketed	GLP-1 receptor agonist	GLP-1R
Lixisenatide (AVE0010)	Lixisenatide (AVE0010)	Sanofi	marketed	GLP-1 receptor agonist	GLP-1R
semaglutide combined with metformin	semaglutide combined with metformin	The First Affiliated Hospital of Xiamen University	marketed	GLP-1 receptor agonist combined with biguanide	GLP-1R; AMPK pathway
Liraglutide + Exercise training	Liraglutide + Exercise training	University of Virginia	marketed	GLP-1 receptor agonist	GLP-1R

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GLP-1 receptor agonist class)

Hanmi Pharmaceutical Company Limited · 30 drugs in this class
Eli Lilly and Company · 8 drugs in this class
Novo Nordisk A/S · 6 drugs in this class
GlaxoSmithKline · 6 drugs in this class
Sanofi · 4 drugs in this class
AstraZeneca · 4 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
Hangzhou Sciwind Biosciences Co., Ltd. · 3 drugs in this class
Jiangsu Hansoh Pharmaceutical Co., Ltd. · 2 drugs in this class
Huons Co., Ltd. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tyroserleutide for injection — Competitive Intelligence Brief. https://druglandscape.com/ci/tyroserleutide-for-injection. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing